Replies to post #207434 on Biotech Values

[RockRat]

Among the cursory arguments against taking a position in FGEN are that it is immensely popular in these parts and that it has a great many moving parts.

These same characteristics did not deter you from taking a position in MNTA :>)

But focus is important in this game.

Regards, RockRat

[dewophile]

I think it is "popular in these parts" in part bc it does NOT have a lot of moving parts and is fairly easy to understand- all of 2 programs, w one accounting for 90% of the current valuation
I do think competition from biosimilar epo, competition from future HIFPH inhibitors, risk inherent w a novel MOA and the fairly high market cap for a development stage bio are all reasonable concerns of course